Psychosexual well-being in women using oral contraceptives containing drospirenone

Functional Neurology

Volumn 24, Issue 2, 2009, Pages 71-75

  Nappi, Rossella E ^a   Albani, Francesca ^a   Tonani, Silvia ^a   Santamaria, Valentine ^a   Pisani, Carla ^a   Terreno, Erica ^a   Martini, Eihs ^a   Polatti, Franco ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

21 7 regimen; 24 4 regimen; Drospirenone; Oral contraceptives; Premenstrual disorders; Sexual function

Indexed keywords

DIENOGEST; DROSPIRENONE; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS GESTODENE; GESTAGEN; ORAL CONTRACEPTIVE AGENT;

DRUG SAFETY; EMOTION; FEMALE; HORMONAL CONTRACEPTION; HUMAN; IMPLANT; INTRAUTERINE CONTRACEPTIVE DEVICE; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; REPRODUCTIVE HEALTH; REVIEW; RISK BENEFIT ANALYSIS; SEXUAL INTERCOURSE; SEXUALITY; TRANSDERMAL PATCH; VAGINA RING; WATER RETENTION; WEIGHT GAIN;

ALDOSTERONE ANTAGONISTS; ANDROSTENES; CHEMISTRY, PHARMACEUTICAL; CONTRACEPTIVES, ORAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGENS; FEMALE; HUMANS; PATIENT SATISFACTION; QUALITY OF LIFE; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; WOMEN'S HEALTH;

EID: 77952148085     PISSN: 03935264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Blumenthal PD, Edelman A. Hormonal contraception. Obstet Gynecol 2008;112:670-684
2. Nappi RE. Sexual well-being in women using oral contraceptives. Gynaecology Forum 2008;13:14-17
3. Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000;95:261-266
4. Ferrari MD. ed. Migraine as a process - challenges in the effective management of migraine. Funct Neurol 2008;23: 153-160
5. Sulak PJ. Continuous oral contraception: changing times. Best Pract Res Clin Obstet Gynaecol 2008;22:355-374
6. Schindler AE, Campagnoli C, Druckmann R et al. Classification and pharmacology of progestins. Maturitas 2008; 61:171-180
7. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 2008;61:151-157
8. Foidart JM. The contraceptive profile of a new oral contraceptive with antimineralocorticoid and antiandrogenic effects. Eur J Contracept Reprod Health Care 2000;5 (Suppi 3):25-33
9. van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R. The effect of 2 combined oral vontraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002;69 (4 Suppl):2-15
10. Freeman EW, Kroll R, Rapkin A et al.; PMS/PMDD Research Group. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Wornens Health Gend Based Med 2001;10:561-569
11. Dinger JC, Heinemann LA, Kūhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 2007;75:344-354
12. Bitzer J, Paoletti AM. Added benefits and user satisfaction with a low-dose oral contraceptive containing drospirenone: results of three multicentre trials. Clin Drug Investig 2009; 29:73-78
13. Mishell DR Jr. An oral contraceptive with 3 approved indications. J Reprod Med 2008;53 (9 Suppl):717-719
14. Rapkin AJ. YAZ in the treatment of premenstrual dysphoric disorder. J Reprod Med 2008;53 (9 Suppl):7297-741
15. Maloney JM, Dietze P Jr, Watson D et al. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial. Obstet Gynecol 2008; 112:773-781
16. Lopez LM, Kaptein AA, Heimerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2009 Apr 15;(2):CD006586.
17. Goldstein I, Meston CM, Davis SR, Traish A eds Women's Sexual Function and Dysfunction. Study, Diagnosis and Treatment. UK; Taylor & Francis 2006
18. Nappi RE, Polatti F. The use of estrogen therapy in women's sexual functioning (CME). J Sex Med 2009;6: 603-616
19. Genazzani AR, Monteleone P, Gambacciani M. Hormonal influence on the central nervous system. Maturitas 2002; 43 (Suppl 1):S11-17
20. Morrell M, Dixen J, Carter S et al. The influence of age and cycling status on sexual arousability in women. Am J Obstet Gynecol 1984;148:66-71
21. Persky H, Dreisbach L, Miller WR et al. The relation of plasma androgen levels to sexual behaviors and attitudes of women. Psychosom Med 1982;44:305-319
22. Schreiner-Engel P, Schiavi RC, Smith H, White D. Sexual arousability and the menstrual cycle. Psychosom Med 1981;43:199-214
23. Salonia A, Nappi RE, Pontillo M et al. Menstrual cycle-related changes in plasma oxytocin are relevant to normal sexual function in healthy women. Horm Behav 2005; 47:164-169
24. Warner P, Bancroft J. Mood, sexuality, oral contraceptives and the menstrual cycle. J Psychosom Res 1988;32:417-427
25. Graham CA, Sherwin BB. The relationship between mood and sexuality in women using an oral contraceptive as a treatment for premenstrual symptoms. Psychoneuroendocrinology 1993;18:273-281
26. McCoy NL, Matyas JR. Oral contraceptives and sexuality in university women. Arch Sex Behav 1996 ;25:73-90
27. Davis AR, Castan̄o PM. Oral contraceptives and libido in women. Annu Rev Sex Res 2004;15:297-320
28. Sanders SA, Graham CA, Bass JL, Bancroft J. A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation. Contraception 2001;64:51-58
29. Oinonen KA, Mazmanian D. To what extent do oral contraceptives influence mood and affect? J Affect Disord 2002; 70:229-240
30. Rapkin AJ, Biggio G, Concas A. Oral contraceptives and neuroactive steroids. Pharmacol Biochem Behav 2006; 84:628-634
31. Rapkin AJ, Morgan M, Sogliano C, Biggio G, Concas A. Decreased neuroactive steroids induced by combined oral contraceptive pills are not associated with mood changes. Fertil Steril 2006;85:1371-1378
32. Joffe H, Cohen LS, Harlow BL. Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration. Am J Obstet Gynecol 2003;189:1523-1530
33. Young EA, Kornstein SG, Harvey AT et al. Influences of hormone-based contraception on depressive symptoms in premenopausal women with major depression. Psychoneuroendocrinology 2007;32:843-853
34. O'Connell K, Davis AR, Kerns J. Oral contraceptives: side effects and depression in adolescent girls. Contraception 2007;75:299-304
35. Caruso S, Agnello C, lntelisano G, Farina M, Di Mari L, Cianci A. Sexual behavior of women taking low-dose oral contraceptive containing 15 microg ethinylestradiol/60 microg gestodene. Contraception 2004;69:237-240
36. Bancroft J, Sherwin BB, Alexander GM, Davidson DW, Walker A. Oral contraceptives, androgens, and the sexuality of young women: II. The role of androgens. Arch Sex Behav 1991;20:121-135
37. Alexander GM, Sherwin BB, Bancroft J, Davidson DW. Testosterone and sexual behavior in oral contraceptive users and nonusers: a prospective study. Horm Behav 1990;24:388-402
38. Kostoglou-Athanassiou I, Athanassiou P, Treacher DF, Wheeler MJ, Forsling ML. Neurohypophysial hormone and melatonin secretion over the natural and suppressed menstrual cycle in premenopausal women. Clin Endocrinol (Oxf) 1998;49:209-216
39. Graham CA, Bancroft J, Doll HA, Greco T, Tanner A. Does oral contraceptive-induced reduction in free testosterone adversely affect the sexuality or mood of women? Psychoneuroendocrinology 2007;32:246-255
40. Greco T, Graham CA, Bancroft J, Tanner A, Doll HA. The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulationscontaining norgestimate and either 35 or 25 microg of ethinyl estradiol. Contraception 2007;76:8-17
41. Muhn P, Krattenmacher R, Beier S, Elger W, Schillinger E.Drospirenone: a novel progestogen with antimineralcorticoid and antiandrogenic activity. Pharmacological characterization in animal models. Contraception 1995; 51:99-110
42. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005; 72:414-421
43. Caruso S, Agnello C, lntelisano G et al. Prospective study on sexual behavior of women using 30 microg ethinylestradiol and 3 mg drospirenone oral contraceptive. Contraception 2005;72:19-23